Treatment News : FDA OKs Oral Isentress to Treat HIV in Children

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 29, 2014

FDA OKs Oral Isentress to Treat HIV in Children

The U.S. Food and Drug Administration (FDA) has approved a new oral suspension form of the integrase inhibitor Isentress (raltegravir) for pediatric use, HIVandHepatitis reports. The indication of this liquid form of the drug is for the treatment of HIV in children who are at least four weeks old and weigh between about 7 and 44 pounds (3 and 20 kilograms).

A single-use packet of the oral suspension of the drug includes 100 milligrams of Isentress suspended in 5 milliliters of water, for an ultimate concentration of 20 mg per mL. The liquid should be drawn into an oral syringe in order to measure the dose and administered within half an hour of mixing. Isentress is also available in chewable tablets for older children and for people who are unable to swallow the standard tablets of the drug.

“We are very pleased that Isentress can now be a part of a treatment regimen for HIV-1 infected infants and children as young as four weeks of age,” Hedy Teppler, executive director of clinical research at Merck Research Laboratories, said in a release.

According to Merck, this new formulation should be available by the summer.

To read the HIVandHepatitis report, click here.

To read the Merck release, click here.

Search: Isentress, raltegravir, HIV, pediatric, children, U.S. Food and Drug Administration, FDA, HIVandHepatitis, oral suspension, liquid dose, Hedy Teppler, Merck.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Is youth leadership important in the HIV/AIDS fight?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.